Articles by Daniel Marsh
Fidelity Canada to Shutter Eight Funds as Retirement Products Outperform
Fidelity Investments Canada is winding down eight funds, with most closures set for late July. Meanwhile, the firm's Freedom 2045 and 2015 retirement funds outperformed their benchmarks in the fourth quarter of 2025.
Global Markets Rally on Geopolitical Ease; Microsoft, Marvell Gain on AI Bets
Global equities advanced Wednesday as signs of easing Middle East tensions spurred a risk-on rally. Microsoft gained on a major AI infrastructure investment, while Marvell Technology surged following a strategic partnership with Nvidia.
CNBC to Broadcast Live from Cboe Options Floor Amid Trading Surge
CNBC will begin daily live broadcasts from the Cboe Global Markets trading floor in Chicago on April 6. The move coincides with record U.S. options trading volume, which reached 15.2 billion contracts in 2025.
Mortgage Rates Hold Near Recent Highs, Adding Pressure to Spring Homebuyers
Key mortgage rates held near multi-month highs on Tuesday, sustaining affordability challenges for prospective homebuyers this spring. Data from major trackers showed continued volatility, with the 10-year Treasury yield hovering around 4.5%.
Dow Rises on Geopolitical Hopes, But Quarterly Losses Mount
The Dow Jones Industrial Average advanced 1.2% to 45,764.14 Tuesday as traders reacted to potential diplomatic developments with Iran. Despite the daily gain, the index is headed for its worst quarterly performance since early 2022.
Stocks Rebound on Geopolitical Hopes, But Quarterly Loss Looms
Major U.S. indices climbed Tuesday, led by the Nasdaq's 2% gain, following reports the Trump administration might end military action in Iran. Despite the rally, the S&P 500 is headed for its steepest quarterly decline in over four years.
Wealth Managers Boost Leveraged Nasdaq ETF Bets Ahead of Market Correction
SEC filings reveal several wealth management firms significantly raised their holdings in leveraged Nasdaq-100 ETFs like TQQQ and QLD in late 2025. These bets are now under pressure as the Nasdaq Composite has entered correction territory.
Pfizer Shares Reach New Peak Amid Divergent Views on Future Growth
Pfizer shares surged to a 52-week high of $28.30, driven by robust quarterly results and promising oncology data. Analysts remain divided on whether the stock's rally is sustainable given looming growth challenges.
Biogen to Acquire Apellis in $5.6B Deal, Adding Rare Disease Portfolio
Biogen has entered an agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion in cash. The deal provides Apellis shareholders $41 per share upfront, with potential additional payments based on sales performance of the eye drug Syfovre.
JPMorgan Commits $80 Billion to Small Business, Expands Private Capital Unit
JPMorgan Chase unveiled a decade-long $80 billion lending program aimed at small businesses and is expanding its private capital team to serve companies staying private longer.